- Leading US centers in food allergy will be involved in an NIH-funded CoFAR study, coordinated by Dr. Sampson and Dr. Jones in collaboration with DBV' team
- CoFAR6 study will help to better characterize the mechanisms of action of epicutaneous immunotherapy
Peanut allergy is associated with a higher frequency of severe life-threatening allergic reactions than other common food allergies, including milk and egg allergies.About DBV Technologies DBV Technologies is developing Viaskin®, an innovative new approach to the treatment of allergies - a major public health issue that is constantly increasing in prevalence. Food allergies represent a true handicap in everyday life for millions of people, constituting a major unmet medical need. DBV Technologies, incorporated in France in 2002, has developed a proprietary, worldwide-patented technology for administering an allergen to intact skin while avoiding transfer to the blood. The Viaskin® technology combines efficacy and safety as part of a treatment that seeks to improve the patient's tolerability of peanuts, and thus considerably lowers the risk of a systemic, allergic reaction in the event of accidental exposure The product's clinically proven safety profile enables the application of effective desensitization techniques in the most severe forms of the allergy. DBV Technologies is focusing on food allergies, including milk and peanut, for which there are currently no effective treatments. DBV Technologies has designed two products: Viaskin® Peanut and Viaskin® Milk. The clinical development program for Viaskin® Peanut has received Fast Track designation from the US Food and Drug Administration and is currently being studies in Phase II program. The company will subsequently develop a Viaskin® patch for young children with house dust mite allergy - a true public health issue because this pathology is a primary risk factor for childhood asthma. DBV Technologies shares are traded on segment C of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345). For more information on DBV Technologies, please visit our website: www.dbv-technologies.com Forward Looking Statement The forward-looking statements, objectives and targets contained herein are based on the Company's management strategy, current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. Furthermore, the Research and Development process involves several stages each of which involve the substantial risk that the Company may fail to achieve its objectives and be forced to abandon its efforts with regards to a product in which it has invested significant sums. Therefore, the Company cannot be certain that favorable results obtained during pre-clinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the product concerned. DBV technologies' business is subject to the risk factors outlined in its registration documents filed with the French Autorité des Marchés Financiers.
NIH-sponsored CoFAR starts a Phase II Viaskin Peanut: http://hugin.info/156437/R/1737627/582681.pdf
CONTACT: DBV Contacts DBV Technologies David Schilansky Chief Financial Officer Tel. : +33(0)1 55 42 78 75 firstname.lastname@example.org US & UK investors The Trout Group Investor Relations Alan S. Roemer Tel. : +1 (646) 378-2945 email@example.com French investors NewCap. Financial Communication and investor relations Emmanuel Huynh / Valentine Brouchot Tel. : +33(0)1 44 71 94 94 firstname.lastname@example.org US press & media Ronald Trahan Associates Inc. Press relations Ronald Trahan, APR Tel. : +1 508 359 4005 email@example.com CoFAR contact Kevin Orozovich Manager, Newsroom The Mount Sinai Medical Center Tel: (212) 241-9200 firstname.lastname@example.org